[admin]

The Growing Need for Characterized Anti-Cancer Compound Libraries

Traditional de novo drug discovery requires multi-million-compound libraries, specialized screening facilities, lengthy timelines, and high cost, while drug safety and efficacy regulation continues to add complexity. Approved and clinical compounds reduce this risk because they carry known bioactivity, safety, and bioavailability profiles — a foundational insight that shapes how TargetMol builds its compound library portfolio.

This challenge is especially pronounced in oncology research. Cancer cells continue to divide, lose normal cell signaling responses, contain abnormal chromatin changes, alter energy metabolism, and induce vascularization. These overlapping biological processes mean that effective anti-cancer compound libraries must be designed with broad mechanistic coverage, verified purity, and clear target annotation — not simply large compound counts. TargetMol’s Comprehensive Anti-Cancer Compound Library solutions are structured directly around this need, offering curated, annotated, and quality-validated collections for tumor research and anti-tumor drug screening.

TargetMol’s Anti-Cancer Compound Library Portfolio

TargetMol’s Compound Library organizes its anti-cancer offerings into three complementary collections, each positioned for a distinct stage of cancer research and drug discovery.

L2100 Anti-cancer Compound Library

The L2100 Anti-cancer compound library is a collection of compounds with anti-tumor activity targeting the metabolism, growth, invasion, and metastasis of tumor cells. It contains 10,240 anti-cancer compounds selected for anti-tumor activity, supporting both high throughput screening (HTS) and high content screening (HCS). Bioactivity and safety have been profiled in preclinical and clinical settings, and the library covers targets including PI3K, HDAC, mTOR, CDK, Aurora Kinase, and JAK, among others involved in tumor biology. Each compound is annotated with structure, target, activity, IC50 value, and biological activity description, and the library is structurally diverse, medicinally active, and cell permeable — qualities verified through NMR and HPLC quality validation.

L2110 Anti-Cancer Approved Drug Library

For researchers who need reliable positive controls, the L2110 Anti-Cancer Approved Drug Library offers 2,020 approved anti-cancer drugs selected from published literature and databases. These compounds are approved by FDA, EMA, or NMPA and come with annotated bioactivity, safety, and bioavailability, making them suitable as positive controls in biological cancer investigation and cancer correlation study. The library spans targets such as PI3K, HDAC, mTOR, CDK, Aurora Kinase, and JAK, and covers disease areas including lung cancer, breast cancer, leukemia, and lymphoma. As with other TargetMol’s Screening Library products, structure, target, activity, IC50 value, and biological activity description are documented, with NMR and HPLC validation of purity and quality.

L2150 Anti-Cancer Drug Library

Bridging the approved and clinical stages, the L2150 Anti-Cancer Drug Library contains 3,755 drugs with demonstrated or potential anticancer activity, drawn from both FDA-approved and clinical trial sources. This library is involved in 15 different cancer research areas, including lung cancer, breast cancer, leukemia, and lymphoma, and its bioactivity and safety have been profiled in preclinical and clinical settings. It is designed to support molecular mechanism study of tumorigenesis and anti-tumor drug repositioning drug discovery, with target coverage spanning PI3K, HDAC, mTOR, CDK, Aurora Kinase, and JAK. Compound annotation again includes structure, target, activity, IC50 value, and biological activity description, validated through NMR and HPLC testing.

Quality Assurance Across the Portfolio

A recurring theme across TargetMol’s anti-cancer libraries is quality validation. Every collection — L2100, L2110, and L2150 — undergoes NMR and HPLC validation for purity and quality, reducing the risk of false results that can arise from impure compounds. Compounds across these libraries share a common structural and activity profile: structurally diverse, medicinally active, and cell permeable, which makes them directly usable in cell-based assays without additional preparation. This consistent documentation standard — structure, target, activity, IC50 value, and biological activity description — allows researchers to interpret screening results with greater confidence, whether they are running a large-scale 10,240-compound screen or working with a smaller, more targeted approved-drug reference set.

Beyond Anti-Cancer: A Broader Ecosystem Supporting Oncology Research

TargetMol’s anti-cancer offerings do not exist in isolation. The L4000 Bioactive Compound Library, which contains more than 19,730 small molecule compounds with known biological activities, explicitly includes Cancer among its covered disease areas, alongside Metabolism, Immunology, and Cardiovascular system. This library is composed in part of the Clinical compound library (L3400), the Preclinical compound library (L3410), and the Approved drug library (L1000), giving researchers a pathway to expand beyond dedicated anti-cancer sets into a broader, development-stage-spanning collection when a research question calls for it. All compounds in this larger library have clear targets, supporting mechanism-based interpretation for teams pursuing drug repurposing, small molecule-induced stem cell differentiation, or target identification work connected to cancer biology.

This layered structure — purpose-built anti-cancer libraries supported by a larger annotated bioactive collection — reflects TargetMol’s broader strategic positioning: supplying curated, annotated, and quality-validated compound libraries designed for drug repurposing, cell differentiation induction, target identification, and high throughput or high content screening across multiple disease research areas.

Who Benefits from TargetMol’s Anti-Cancer Libraries

TargetMol’s compound library solutions are built for scientists, drug discovery researchers, pharmaceutical companies, and drug discovery project teams working across oncology research areas such as cancer target identification, tumorigenesis mechanism study, and anti-tumor drug repositioning. Because the anti-cancer libraries span the full spectrum from large-scale screening sets (L2100) to approved-drug positive controls (L2110) to combined approved-and-clinical compound sets (L2150), research teams can select the library — or combination of libraries — that matches their specific stage of investigation, whether that is early mechanism discovery, drug repositioning, or confirmatory screening against known cancer targets.

 

Conclusion

Cancer research demands compound resources that go beyond raw scale, requiring verified purity, clear target annotation, and documented biological activity. TargetMol addresses this need through a structured portfolio — the L2100 Anti-cancer compound library, L2110 Anti-Cancer Approved Drug Library, and L2150 Anti-Cancer Drug Library — each validated through NMR and HPLC testing and annotated with structure, target, activity, IC50 value, and biological activity description. Supported by the broader L4000 Bioactive Compound Library and TargetMol’s overall value proposition of accelerating hit identification and drug optimization through ready-to-screen, characterized compound libraries, TargetMol’s Compound Library provides a comprehensive foundation for drug repurposing, mechanism study, and anti-tumor drug screening across oncology research programs.

http://www.targetmol.com
TargetMol Chemicals Inc.

[Author]

Posts